Clinical Research Directory
Browse clinical research sites, groups, and studies.
Optimum Induction Therapy of Low-risk APL
Sponsor: Peking University People's Hospital
Summary
Despite the high cure probability for acute promyelocytic leukemia (APL), a minority of patients will relapse and the risk factors for relapse are unclear. The goal of this clinical trial is to compare the effectiveness and safety of induction of oral all-trans retinoic acid (ATRA) and realgar-indigo naturalis formula (RIF) combined with oral etoposide or daunorubicin as cytoreductive therapies in low-risk APL. The present study was to explored a cytoreduction of an oral etoposide for low-risk APL with dual induction of ATRA and RIF as a high efficacy, low recurrence, and more convenient all-oral regimen.
Official title: Optimum Induction Therapy of Low-risk Acute Promyelocytic Leukemia With All Oral Drugs
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
74
Start Date
2023-01-01
Completion Date
2024-12-31
Last Updated
2024-05-10
Healthy Volunteers
No
Interventions
Etoposide
Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
Daunorubicin
Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
Locations (1)
Peking University Institute of Hematology
Beijing, Beijing Municipality, China